425 related articles for article (PubMed ID: 27692902)
1. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
3. No association of DNM3 with age of onset in Asian Parkinson's disease.
Foo JN; Tan LC; Au WL; Prakash KM; Liu J; Tan EK
Eur J Neurol; 2019 May; 26(5):827-829. PubMed ID: 30133089
[TBL] [Abstract][Full Text] [Related]
4. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
[TBL] [Abstract][Full Text] [Related]
5. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
Brown EE; Blauwendraat C; Trinh J; Rizig M; Nalls MA; Leveille E; Ruskey JA; Jonvik H; Tan MMX; Bandres-Ciga S; Hassin-Baer S; Brockmann K; Infante J; Tolosa E; Ezquerra M; Ben Romdhan S; Benmahdjoub M; Arezki M; Mhiri C; Hardy J; Singleton AB; Alcalay RN; Gasser T; Grosset DG; Williams NM; Pittman A; Gan-Or Z; Fernandez-Santiago R; Brice A; Lesage S; Farrer M; Wood N; Morris HR;
Neurobiol Aging; 2021 Jan; 97():148.e17-148.e24. PubMed ID: 32873436
[TBL] [Abstract][Full Text] [Related]
7. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
[TBL] [Abstract][Full Text] [Related]
8. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
[TBL] [Abstract][Full Text] [Related]
9. No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease.
Berge-Seidl V; Pihlstrøm L; Wszolek ZK; Ross OA; Toft M
Neurobiol Aging; 2019 Feb; 74():236.e1-236.e5. PubMed ID: 30340792
[TBL] [Abstract][Full Text] [Related]
10. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
11. Role of
Sadhukhan D; Biswas A; Bhaduri A; Sarkar N; Biswas A; Das SK; Banerjee TK; Ray K; Ray J
Indian J Med Res; 2020 Jun; 151(6):592-597. PubMed ID: 32719233
[TBL] [Abstract][Full Text] [Related]
12. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
[TBL] [Abstract][Full Text] [Related]
13. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
14. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
15. Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors.
Lüth T; König IR; Grünewald A; Kasten M; Klein C; Hentati F; Farrer M; Trinh J
Mov Disord; 2020 Oct; 35(10):1854-1858. PubMed ID: 32875616
[TBL] [Abstract][Full Text] [Related]
16. Evidence for prehistoric origins of the G2019S mutation in the North African Berber population.
Ben El Haj R; Salmi A; Regragui W; Moussa A; Bouslam N; Tibar H; Benomar A; Yahyaoui M; Bouhouche A
PLoS One; 2017; 12(7):e0181335. PubMed ID: 28723952
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
[TBL] [Abstract][Full Text] [Related]
18. Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
Lüth T; Gabbert C; Koch S; König IR; Caliebe A; Laabs BH; Hentati F; Sassi SB; Amouri R; Spielmann M; Klein C; Grünewald A; Farrer MJ; Trinh J
Mov Disord; 2023 Oct; 38(10):1837-1849. PubMed ID: 37482924
[TBL] [Abstract][Full Text] [Related]
19. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
Latourelle JC; Sun M; Lew MF; Suchowersky O; Klein C; Golbe LI; Mark MH; Growdon JH; Wooten GF; Watts RL; Guttman M; Racette BA; Perlmutter JS; Ahmed A; Shill HA; Singer C; Goldwurm S; Pezzoli G; Zini M; Saint-Hilaire MH; Hendricks AE; Williamson S; Nagle MW; Wilk JB; Massood T; Huskey KW; Laramie JM; DeStefano AL; Baker KB; Itin I; Litvan I; Nicholson G; Corbett A; Nance M; Drasby E; Isaacson S; Burn DJ; Chinnery PF; Pramstaller PP; Al-hinti J; Moller AT; Ostergaard K; Sherman SJ; Roxburgh R; Snow B; Slevin JT; Cambi F; Gusella JF; Myers RH
BMC Med; 2008 Nov; 6():32. PubMed ID: 18986508
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 mutations and Parkinson's disease in Sardinia--A Mediterranean genetic isolate.
Cossu G; van Doeselaar M; Deriu M; Melis M; Molari A; Di Fonzo A; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2007 Feb; 13(1):17-21. PubMed ID: 17064949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
